
PF-3450074
CAS No. 1352879-65-2
PF-3450074( PF3450074 | PF-74 | PF74 )
Catalog No. M11434 CAS No. 1352879-65-2
PF-3450074 (PF74) is a small molecule HIV capsid protein, destabilized the viral capsid in vitro; acts at an early stage of HIV-1 infection and inhibits reverse transcription in target cells.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 39 | Get Quote |
![]() ![]() |
10MG | 71 | Get Quote |
![]() ![]() |
25MG | 120 | Get Quote |
![]() ![]() |
50MG | 203 | Get Quote |
![]() ![]() |
100MG | 357 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NamePF-3450074
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-3450074 (PF74) is a small molecule HIV capsid protein, destabilized the viral capsid in vitro; acts at an early stage of HIV-1 infection and inhibits reverse transcription in target cells.
-
DescriptionPF-3450074 (PF74) is a small molecule HIV capsid protein, destabilized the viral capsid in vitro; acts at an early stage of HIV-1 infection and inhibits reverse transcription in target cells, induced the rapid dissolution of the HIV-1 capsid; PF74 antiviral activity is promoted by binding of the host protein cyclophilin A to the HIV-1 capsid, and PF74 and cyclosporine exhibited mutual antagonism.
-
In VitroPF-3450074 (PF-74) exhibits anti-viral activities against HIV wild type NL4-3 andHIV T107N mutant with EC50 values of 0.72 μM and 4.5μM, respectively.PF-3450074 (PF-74) displays a good potency in primary human peripheral blood mononuclear cells (PBMCs), inhibits HIV-193RW025, HIV-1JR-CSF and HIV-193MW965 with IC50 values of 1.5 ± 0.9 μM; 0.6 ± 0.20 μM; and 0.6 ± 0.10 μM, respectively. This compound shows Median IC50?and CC50?values of 0.9 ± 0.5 μM and 90.5 ± 5.9 μM, respectively.The KD?for the interaction between?PF-74?and the CA hexamer, derived in the same manner as for NUP153, is determined to be 176 ± 78 nM.PF-3450074 (PF-74) (10 μM; 8 hours) results in a marked reduction in late products of reverse transcription in HeLa-P4 cells with DNase I-treated stocks of Env-defective HIV-1 (R9.Env-). RT-PCR Cell Line:HeLa-P4 cells Concentration:10 μMIncubation Time:8 hours Result:Inhibited HIV-1 reverse transcription in target cells.
-
In Vivo——
-
SynonymsPF3450074 | PF-74 | PF74
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1352879-65-2
-
Formula Weight425.532
-
Molecular FormulaC27H27N3O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (587.52 mM)
-
SMILESO=C(N[C@@H](CC1=CC=CC=C1)C(N(C)C2=CC=CC=C2)=O)CC3=C(C)NC4=C3C=CC=C4
-
Chemical Name2-Methyl-N-[(1S)-2-(methylphenylamino)-2-oxo-1-(phenylmethyl)ethyl]- 1H-indole-3-acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Shi J, et al. J Virol. 2011 Jan;85(1):542-9.
2. Shi J, et al. J Virol. 2015 Jan;89(1):208-19.
3. Zhou J, et al. J Virol. 2015 Sep;89(17):9068-79.
4. Saito A, et al. J Virol. 2016 May 27;90(12):5808-5823.
molnova catalog



related products
-
Dolutegravir sodium
Dolutegravir sodium (GSK-1349572A) is a potent, next-generation HIV integrase (IN) inhibitor, inhibits HIV-1 integrase-catalyzed strand transfer with IC50 of 2.7 nM.
-
YLC2-155
YLC2-155 is a novel potent HIV-1 reverse transcriptase (RT) inhibitor that inhibits both polymerase (IC50=2.6 uM) and RNase H function (IC50=0.65 uM) of RT.
-
Enfuvirtide
Enfuvirtide (INN) is an HIV fusion inhibitor, the first of a class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection.